Vivek Subbiah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5298288/publications.pdf

Version: 2024-02-01

453 papers	17,312 citations	25014 57 h-index	20943 115 g-index
461 all docs	461 docs citations	461 times ranked	21838 citing authors

#	Article	IF	Citations
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clinical Genitourinary Cancer, 2022, 20, e16-e24.	0.9	1
2	Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusionâ€"Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist, 2022, 27, 22-29.	1.9	6
3	Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist, 2022, 27, 13-21.	1.9	9
4	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nature Reviews Clinical Oncology, 2022, 19, 51-69.	12.5	101
5	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncology, The, 2022, 23, 53-64.	5.1	165
6	Assessment of tumour-agnostic therapies in basket trials. Lancet Oncology, The, 2022, 23, e7.	5.1	3
7	Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials.. Journal of Clinical Oncology, 2022, 40, 577-577.	0.8	0
8	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology, 2022, 5, 26-30.	0.6	1
9	Impact of tissue-agnostic approvals for patients with sarcoma. Trends in Cancer, 2022, 8, 135-144.	3.8	11
10	A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibodyâ€"Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. Molecular Cancer Therapeutics, 2022, 21, 625-634.	1.9	4
11	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. Journal of Experimental and Clinical Cancer Research, 2022, 41, 51.	3.5	9
12	FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Annals of Oncology, 2022, 33, 522-533.	0.6	93
13	A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS584-TPS584.	0.8	2
14	Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer. Cancer Research, 2022, 82, OT2-01-02-OT2-01-02.	0.4	0
15	ROAR trial: which treatment is effective after progression? â€" Authors' reply. Lancet Oncology, The, 2022, 23, e94.	5.1	1
16	Think Globally, Act Locally: Globalizing Precision Oncology. Cancer Discovery, 2022, 12, 886-888.	7.7	4
17	Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600â€"Mutant Tumors. Molecular Cancer Therapeutics, 2022, 21, 871-878.	1.9	23
18	Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1^{N546K} Mutation. JCO Precision Oncology, 2022, 6, e2100371.	1.5	4

#	Article	IF	Citations
19	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical Cancer Research, 2022, 28, 2762-2770.	3.2	10
20	Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Scientific Reports, 2022, 12, .	1.6	7
21	Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Nonâ€"Small Cell Lung Cancer. JAMA Network Open, 2022, 5, e2214046.	2.8	15
22	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nature Communications, 2022, 13, .	5.8	28
23	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision Oncology, 2022, , .	1.5	15
24	Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?. Clinical Cancer Research, 2022, 28, 3408-3410.	3.2	2
25	Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research, 2022, 28, 2969-2969.	3.2	1
26	Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. European Journal of Cancer, 2022, 172, 340-348.	1.3	12
27	Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass. Oncology, 2021, 99, 62-64.	0.9	4
28	Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head and Neck, 2021, 43, E7-E12.	0.9	42
29	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends in Cancer, 2021, 7, 15-28.	3.8	61
30	Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Annals of Oncology, 2021, 32, 261-268.	0.6	143
31	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402.	1.5	7
32	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptorâ˜positive Metastatic Breast Cancer or Other Solid Tumors. Clinical Cancer Research, 2021, 27, 1247-1255.	3.2	5
33	Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposureâ€"response analysis. Cancer Chemotherapy and Pharmacology, 2021, 87, 113-124.	1.1	4
34	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Investigational New Drugs, 2021, 39, 829-835.	1.2	8
35	Current update on gallbladder carcinoma. Abdominal Radiology, 2021, 46, 2474-2489.	1.0	23
36	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23

#	Article	IF	Citations
37	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist, 2021, 26, 558-e1098.	1.9	18
38	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. British Journal of Cancer, 2021, 124, 1533-1539.	2.9	20
39	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clinical Cancer Research, 2021, 27, 3050-3060.	3.2	24
40	Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game. Clinical Cancer Research, 2021, 27, 2672-2674.	3.2	7
41	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. Npj Precision Oncology, 2021, 5, 21.	2.3	12
42	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	12.5	103
43	First-in-Human Phase I Study of ABBV-085, an Antibodyâ€"Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3556-3566.	3.2	21
44	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multiâ€arm phase Ib study. Investigational New Drugs, 2021, 39, 1357-1365.	1.2	5
45	Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open, 2021, 6, 100079.	2.0	7
46	Overview of Ocular Side Effects of Selinexor. Oncologist, 2021, 26, 619-623.	1.9	5
47	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist, 2021, 26, 588-596.	1.9	42
48	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. OncoTargets and Therapy, 2021, Volume 14, 3037-3049.	1.0	2
49	Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treatment Reviews, 2021, 96, 102179.	3.4	56
50	Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.. Journal of Clinical Oncology, 2021, 39, 3079-3079.	0.8	6
51	Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Annals of Oncology, 2021, 32, 817-819.	0.6	27
52	The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. Npj Precision Oncology, 2021, 5, 48.	2.3	30
53	Advances in cancer research dissemination through the pandemic and beyond. Annals of Oncology, 2021, 32, 689-693.	0.6	0
54	Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Nonâ€"Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clinical Cancer Research, 2021, 27, 4160-4167.	3.2	64

#	Article	IF	Citations
55	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncology, The, 2021, 22, 959-969.	5.1	222
56	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG). , 2021, , .		5
57	Tissue is Still the issue for Precision Oncology: A Novel Web-Based Platform for Lesion Selection and Biopsy Specimen Acquisition. Journal of Immunotherapy and Precision Oncology, 2021, , .	0.6	1
58	Precision therapy for RET-altered cancers with RET inhibitors. Trends in Cancer, 2021, 7, 1074-1088.	3.8	87
59	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open, 2021, 6, 100172.	2.0	9
60	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes and Endocrinology,the, 2021, 9, 491-501.	5.5	192
61	Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precision Oncology, 2021, 5, 1325-1338.	1.5	14
62	Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers. Molecular Cancer Therapeutics, 2021, 20, 1769-1776.	1.9	23
63	A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research, 2021, 27, 6366-6375.	3.2	16
64	The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Medicine, 2021, 19, 209.	2.3	13
65	Right to Try, expanded access use, Project Facilitate, and clinical trial reform. Annals of Oncology, 2021, 32, 1083-1086.	0.6	5
66	A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncology Research and Treatment, 2021, 44, 547-556.	0.8	11
67	COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining. Journal of Immunotherapy and Precision Oncology, 2021, 4, 64-66.	0.6	8
68	Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench. Oncotarget, 2021, 13, 13-15.	0.8	0
69	18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Current Problems in Cancer, 2021, 45, 100797.	1.0	3
70	Assessment of Alectinib vs Ceritinib in ALK-Positive Nonâ€"Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data. JAMA Network Open, 2021, 4, e2126306.	2.8	13
71	Optimizing antiâ€"body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology. Current Problems in Cancer, 2021, 45, 100799.	1.0	2
72	Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. Cancers, 2021, 13, 5249.	1.7	4

#	Article	IF	Citations
73	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Current Problems in Cancer, 2021, 45, 100794.	1.0	4
74	Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Nonâ€"Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2134299.	2.8	13
75	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. Npj Precision Oncology, 2021, 5, 99.	2.3	2
76	Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay inÂsporadic medullary thyroid carcinoma. Surgery, 2020, 167, 80-86.	1.0	8
77	The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell, 2020, 180, 9-14.	13.5	45
78	Imaging of acute abdomen in cancer patients. Abdominal Radiology, 2020, 45, 2287-2304.	1.0	11
79	Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers, 2020, 12, 2636.	1.7	4
80	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587.	3.2	16
81	Exclusion of Older Adults in COVID-19 Clinical Trials. Mayo Clinic Proceedings, 2020, 95, 2293-2294.	1.4	5
82	A global effort to understand the riddles of COVID-19 and cancer. Nature Cancer, 2020, 1, 943-945.	5.7	14
83	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer, 2020, 150, 90-96.	0.9	18
84	EZH2 inhibition for epithelioid sarcoma and follicular lymphoma. Lancet Oncology, The, 2020, 21, 1388-1390.	5.1	10
85	Testing for COVID-19 in patients with cancer. EClinicalMedicine, 2020, 23, 100374.	3.2	8
86	Progresses Toward Precision Medicine in RET-altered Solid Tumors. Clinical Cancer Research, 2020, 26, 6102-6111.	3.2	39
87	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open, 2020, 5, e001073.	2.0	1
88	The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) â‰¥10: a decision centered on empowering patients and their physicians. Annals of Oncology, 2020, 31, 1115-1118.	0.6	161
89	Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. European Journal of Cancer, 2020, 136, 176-185.	1.3	27
90	Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer, 2020, 6, 797-810.	3.8	169

#	Article	IF	Citations
91	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open, 2020, 5, e000799.	2.0	45
92	Dual inhibition of BRAF and mTOR in BRAFV600E-mutant pediatric, adolescent, and young adult brain tumors. Journal of Physical Education and Sports Management, 2020, 6, a005041.	0.5	6
93	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	13.9	454
94	Efficacy of Selpercatinib in RET Fusionâ€"Positive Nonâ€"Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 813-824.	13.9	505
95	Phase I Study of P-cadherinâ€"targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clinical Cancer Research, 2020, 26, 5830-5842.	3.2	17
96	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncology, The, 2020, 21, 1234-1243.	5.1	297
97	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open, 2020, 5, e000866.	2.0	34
98	Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers, 2020, 12, 2307.	1.7	40
99	Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. JCO Precision Oncology, 2020, 4, 1302-1306.	1.5	20
100	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer â€" Authors' reply. Lancet Oncology, The, 2020, 21, e516.	5.1	7
101	Patient-Centered, Physician-Investigator Friendly Pragmatic Phase I/II Trial Designsâ€"The 4P Model. Mayo Clinic Proceedings, 2020, 95, 2566-2568.	1.4	0
102	Managing Cancer Care during the COVID-19 Pandemic and Beyond. Trends in Cancer, 2020, 6, 533-535.	3.8	25
103	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
104	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931.	3.2	50
105	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers, 2020, 12, 710.	1.7	3
106	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Molecular Cancer Therapeutics, 2020, 19, 1165-1172.	1.9	15
107	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncology, The, 2020, 21, 645-654.	5.1	247
108	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers, 2020, 12, 1768.	1.7	20

#	Article	IF	Citations
109	Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	7.7	93
110	Advances in Targeting RET-Dependent Cancers. Cancer Discovery, 2020, 10, 498-505.	7.7	96
111	Molecular Imaging with 3â€²-deoxy-3â€²[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics, 2020, 10, 125.	1.3	5
112	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific Reports, 2020, 10, 3080.	1.6	10
113	State-of-the-Art Strategies for Targeting RET-Dependent Cancers. Journal of Clinical Oncology, 2020, 38, 1209-1221.	0.8	172
114	Cannabidiol (CBD) Oil, Cancer, and Symptom Management: A Google Trends Analysis of Public Interest. Journal of Alternative and Complementary Medicine, 2020, 26, 346-348.	2.1	9
115	Early Response Assessment to Targeted Therapy Using 3â€²-deoxy-3â€²[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer. Diagnostics, 2020, 10, 26.	1.3	11
116	RET Solvent Front Mutations Mediate AcquiredÂResistance to Selective RET Inhibition inÂRET-Driven Malignancies. Journal of Thoracic Oncology, 2020, 15, 541-549.	0.5	189
117	Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. Trends in Cancer, 2020, 6, 181-191.	3.8	82
118	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
119	223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open, 2020, 5, e000635.	2.0	13
120	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Experimental Hematology and Oncology, 2020, 9, 7.	2.0	11
121	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.. Journal of Clinical Oncology, 2020, 38, 109-109.	0.8	49
122	The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naÃ¯ve RET-driven cancer models.. Journal of Clinical Oncology, 2020, 38, 3616-3616.	0.8	32
123	Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.. Journal of Clinical Oncology, 2020, 38, 9516-9516.	0.8	17
124	Role of Sodium Fluoride-PET in Primary Bone Tumors. , 2020, , 69-76.		0
125	Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.. Journal of Clinical Oncology, 2020, 38, 3606-3606.	0.8	7
126	Efficacy of Vemurafenib in Patients With Nonâ€"Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2019, 3, 1-9.	1.5	31

#	Article	IF	Citations
127	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research, 2019, 25, 5832-5842.	3.2	64
128	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers, 2019, 11, 1283.	1.7	19
129	Of mice and men: lost in translation. Annals of Oncology, 2019, 30, 499-500.	0.6	7
130	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research, 2019, 25, 5475-5484.	3.2	17
131	Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3â€²-deoxy-3â€² [(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation. BMJ Case Reports, 2019, 12, e218979.	0.2	2
132	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers, 2019, 11, 677.	1.7	20
133	Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology. BMJ Case Reports, 2019, 12, e218839.	0.2	3
134	Precision Oncology in Sarcomas: Divide and Conquer. JCO Precision Oncology, 2019, 3, 1-16.	1.5	14
135	Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open, 2019, 4, e000439.	2.0	16
136	Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. Case Reports in Oncology, 2019, 12, 7-13.	0.3	14
137	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research, 2019, 25, 3802-3810.	3.2	42
138	Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. Oncologist, 2019, 24, 1291-1293.	1.9	5
139	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precision Oncology, 2019, 3, 1-10.	1.5	6
140	Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. JCO Precision Oncology, 2019, 3, 1-11.	1.5	9
141	Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19â€"FGFR4â€"KLB Pathway Inhibition. Cancer Discovery, 2019, 9, 1646-1649.	7.7	14
142	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiationâ€"Related Abscopal Responses. Cancer Immunology Research, 2019, 7, 1903-1909.	1.6	86
143	Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Nonâ€"Small-Cell Lung Cancer. JCO Precision Oncology, 2019, 3, 1-6.	1.5	5
144	The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. Oncologist, 2019, 24, 1-3.	1.9	73

#	Article	IF	Citations
145	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF â€mutated melanoma and other advanced malignancies. Cancer, 2019, 125, 463-472.	2.0	10
146	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. Journal of Clinical Oncology, 2019, 37, 6018-6018.	0.8	34
147	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9008-9008.	0.8	75
148	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research, 2019, 21, e10348.	2.1	13
149	Personalizing Precision Oncology: From Light Microscope to Molecular Microscope. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 886-888.	2.3	0
150	Vandetanib photoinduced cutaneous toxicities. Cutis, 2019, 103, E24-E29.	0.4	5
151	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer, 2018, 118, 763-769.	2.9	28
152	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. Journal of Immunotherapy, 2018, 41, 284-291.	1.2	11
153	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer, 2018, 120, 137-141.	0.9	29
154	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Molecular Cancer Therapeutics, 2018, 17, 1595-1601.	1.9	30
155	Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discovery, 2018, 8, 836-849.	7.7	298
156	Selective RET kinase inhibition for patients with RET-altered cancers. Annals of Oncology, 2018, 29, 1869-1876.	0.6	304
157	Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Annals of Oncology, 2018, 29, 1445-1453.	0.6	103
158	Hypopigmented Skin Lesions After Immunotherapy. JAMA Oncology, 2018, 4, 1118.	3.4	9
159	Autoimmune hypophysitis. Lancet Oncology, The, 2018, 19, e123.	5.1	6
160	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends in Cancer, 2018, 4, 101-109.	3.8	56
161	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist, 2018, 23, 360-366.	1.9	36
162	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	2.9	7

#	Article	IF	Citations
163	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Current Oncology Reports, 2018, 20, 37.	1.8	27
164	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188.	3.2	127
165	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Investigational New Drugs, 2018, 36, 416-423.	1.2	17
166	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs, 2018, 36, 601-607.	1.2	90
167	Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 43-51.	3.2	77
168	Vemurafenib for BRAF V600â€“Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. JAMA Oncology, 2018, 4, 384.	3.4	280
169	Phase I Dose-Escalation Study of Antiâ€“CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Molecular Cancer Therapeutics, 2018, 17, 671-676.	1.9	33
170	Precision oncology: East meets West. International Journal of Cancer, 2018, 142, 1734-1737.	2.3	1
171	Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. Journal of Computer Assisted Tomography, 2018, 42, 357-364.	0.5	0
172	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	1.2	149
173	Myeloid/lymphoid neoplasms withFGFR1rearrangement. Leukemia and Lymphoma, 2018, 59, 1672-1676.	0.6	53
174	High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	1.0	9
175	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	1.0	5
176	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precision Oncology, 2018, 2, 1-12.	1.5	13
177	BRAF Inhibition in BRAF^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	0.8	247
178	Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	39
179	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600â€“Mutant Anaplastic Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 7-13.	0.8	630
180	Response to Mammalian Target of Rapamycinâ€“Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation. JCO Precision Oncology, 2018, 2, 1-6.	1.5	2

#	Article	IF	Citations
181	Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precision Oncology, 2018, 2, 1-11.	1.5	8
182	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. JCO Precision Oncology, 2018, 2, 1-19.	1.5	2
183	Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. Annals of Oncology, 2018, 29, viii33.	0.6	6
184	Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600Eâ€"mutated anaplastic thyroid cancer (ATC). Annals of Oncology, 2018, 29, viii645-viii646.	0.6	16
185	Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Annals of Oncology, 2018, 29, 2396-2398.	0.6	52
186	OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S349-S350.	0.5	27
187	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemotherapy and Pharmacology, 2018, 82, 877-885.	1.1	5
188	Mining Public Databases for Precision Oncology. Trends in Cancer, 2018, 4, 463-465.	3.8	13
189	Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Annals of Oncology, 2018, 29, 1880-1882.	0.6	27
190	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. Journal of Cutaneous Pathology, 2018, 45, 786-790.	0.7	18
191	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clinical Cancer Research, 2018, 24, 3845-3856.	3.2	35
192	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clinical Cancer Research, 2018, 24, 4865-4873.	3.2	68
193	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. Expert Review of Precision Medicine and Drug Development, 2018, 3, 205-213.	0.4	7
194	Abstract CT024: Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. Cancer Research, 2018, 78, CT024-CT024.	0.4	6
195	Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors. , 2018, , .		23
196	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). Blood, 2018, 132, 391-391.	0.6	40
197	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.. Journal of Clinical Oncology, 2018, 36, 102-102.	0.8	87
198	Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.. Journal of Clinical Oncology, 2018, 36, 11519-11519.	0.8	6

#	Article	IF	Citations
199	A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.. Journal of Clinical Oncology, 2018, 36, 2579-2579.	0.8	1
200	Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 9035-9035.	0.8	10
201	Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125.. Journal of Clinical Oncology, 2018, 36, e15150-e15150.	0.8	2
202	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget, 2018, 9, 28842-28848.	0.8	4
203	Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer. Oncotarget, 2018, 9, 33258-33270.	0.8	9
204	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget, 2018, 9, 33232-33243.	0.8	26
205	Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment.. Journal of Clinical Oncology, 2018, 36, 67-67.	0.8	0
206	Analysis of patient related and trial related factors leading to non-participation of patients with advanced cancer in immunotherapy clinical trials: Implications for modifying eligibility criteria.. Journal of Clinical Oncology, 2018, 36, e15066-e15066.	0.8	0
207	TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes.. Journal of Clinical Oncology, 2018, 36, 12052-12052.	0.8	0
208	Expanding enrollment of underrepresented populations on early phase clinical trials: An analysis of participation among adolescent and young adults (AYA) with advanced cancers on phase I clinical trials.. Journal of Clinical Oncology, 2018, 36, e18714-e18714.	0.8	1
209	A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.. Journal of Clinical Oncology, 2018, 36, 2541-2541.	0.8	0
210	Bringing wearable devices into oncology practice: fitting smart technology in the clinic. Discovery Medicine, 2018, 26, 261-270.	0.5	5
211	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	3.2	53
212	First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 324-333.	1.2	81
213	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. British Journal of Cancer, 2017, 116, 1402-1407.	2.9	54
214	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 509.	3.4	154
215	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clinical Cancer Research, 2017, 23, 5648-5656.	3.2	50
216	Debunking the Delusion That Precision Oncology Is an Illusion. Oncologist, 2017, 22, 881-882.	1.9	23

#	Article	IF	Citations
217	Towards precision oncology in RET-aberrant cancers. Cell Cycle, 2017, 16, 813-814.	1.3	17
218	Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clinical Cancer Research, 2017, 23, 4027-4034.	3.2	34
219	MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Annals of Oncology, 2017, 28, 642-650.	0.6	41
220	The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Current Oncology Reports, 2017, 19, 78.	1.8	32
221	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. Journal of the National Cancer Institute, 2017, 109, .	3.0	16
222	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research, 2017, 23, 4155-4162.	3.2	4
223	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports, 2017, 7, 15963.	1.6	21
224	Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 863-866.	2.3	22
225	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58
226	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology, 2017, 92, 14-20.	0.9	3
227	RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clinical Cancer Research, 2017, 23, 1988-1997.	3.2	186
228	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research, 2017, 23, 1388-1396.	3.2	261
229	Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1315.	0.4	18
230	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
231	Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. Diagnostics, 2017, 7, 10.	1.3	38
232	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget, 2017, 8, 39254-39267.	0.8	62
233	An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3â€²-deoxy-3â€²[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics, 2017, 7, 20.	1.3	6
234	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight, 2017, 2, .	2.3	26

#	Article	IF	Citations
235	The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?. Translational Gastroenterology and Hepatology, 2017, 2, 81-81.	1.5	3
236	Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors. Cancer Research, 2017, 77, CT091-CT091.	0.4	11
237	Abstract CT111: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies. Cancer Research, 2017, 77, CT111-CT111.	0.4	7
238	Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 1524-1524.	0.8	1
239	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. Journal of Clinical Oncology, 2017, 35, 2004-2004.	0.8	1
240	First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.. Journal of Clinical Oncology, 2017, 35, 2584-2584.	0.8	25
241	SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients.. Journal of Clinical Oncology, 2017, 35, 2588-2588.	0.8	1
242	Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600Eâ€"mutated anaplastic thyroid cancer (ATC).. Journal of Clinical Oncology, 2017, 35, 6023-6023.	0.8	16
243	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF^{V600} mutation.. Journal of Clinical Oncology, 2017, 35, 9074-9074.	0.8	10
244	Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy.. Journal of Clinical Oncology, 2017, 35, e14610-e14610.	0.8	4
245	EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial.. Journal of Clinical Oncology, 2017, 35, TPS2604-TPS2604.	0.8	14
246	Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary.. Journal of Clinical Oncology, 2017, 35, TPS3103-TPS3103.	0.8	2
247	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience, 2017, 4, 47-56.	0.9	21
248	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	0.8	5
249	Personalized Medicine in Hereditary Cancer Syndromes. , 2017, , 199-225.		0
250	Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types.. Journal of Clinical Oncology, 2017, 35, 2537-2537.	0.8	1
251	Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations.. Journal of Clinical Oncology, 2017, 35, 11019-11019.	0.8	0
252	Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies.. Journal of Clinical Oncology, 2017, 35, TPS2603-TPS2603.	0.8	0

#	Article	IF	Citations
253	Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 11567-11567.	0.8	0
254	Clinical next generation sequencing for precision oncology in rare cancers.. Journal of Clinical Oncology, 2017, 35, 2582-2582.	0.8	0
255	Bayesian AI to delineate molecular signatures of patient susceptibility to potential hematologic events in a phase I study of BPM31510 (ubidecarenone) in solid tumors.. Journal of Clinical Oncology, 2017, 35, e14042-e14042.	0.8	0
256	Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance.. Journal of Clinical Oncology, 2017, 35, 2583-2583.	0.8	0
257	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers.. Journal of Clinical Oncology, 2017, 35, 2526-2526.	0.8	0
258	Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.. Journal of Clinical Oncology, 2017, 35, 11551-11551.	0.8	0
259	Immuno-oncology and the elderly: A comparative analysis of participation and toxicities of senior adults aged 65 years and above vs mid age and adolescent/young adult patients on immunotherapy-based phase I clinical trials.. Journal of Clinical Oncology, 2017, 35, 10034-10034.	0.8	0
260	Abstract CT097: Phase 1 study of FF-21101(90Y), a radioimmunotherapeutic targeting P-cadherin, in advanced solid tumors. , 2017, , .		0
261	Abstract 3291: Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials. , 2017, , .		0
262	Abstract 642: Detection of circulating antibodies against KRAS in patients with advanced cancers. , 2017, , .		0
263	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	0.8	0
264	Integration of supportive care in immuno-oncology trials: Investigating the incidence and severity of immune-related toxicities among older adults versus mid-age patients on immunotherapy-based phase I clinical trials.. Journal of Clinical Oncology, 2017, 35, 152-152.	0.8	0
265	Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents.. Journal of Clinical Oncology, 2017, 35, 149-149.	0.8	4
266	The Senses and Cancer. Journal of Palliative Medicine, 2016, 19, 467-467.	0.6	0
267	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer, 2016, 122, 702-711.	2.0	81
268	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448.	1.6	12
269	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	1.3	20
270	Headache in a patient with renal cell carcinoma.. European Journal of Internal Medicine, 2016, 32, e3-e4.	1.0	1

#	Article	IF	Citations
271	Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology, 2016, 90, 339-346.	0.9	43
272	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research, 2016, 76, 3690-3701.	0.4	203
273	Genomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics, 2016, 15, 533-547.	1.9	63
274	Universal Genomic Testing Needed to Win the War Against Cancer. JAMA Oncology, 2016, 2, 719.	3.4	32
275	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology, 2016, 77, 973-977.	1.1	34
276	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute, 2016, 108, djw182.	3.0	49
277	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 2475-2485.	1.9	73
278	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for earlyâ€phase oncology clinical trials. Cancer, 2016, 122, 3401-3409.	2.0	50
279	Jaundice (Hyperbilirubinemia) in Cancer. JAMA Oncology, 2016, 2, 1103.	3.4	6
280	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
281	Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology, 2016, 91, 348-353.	0.9	29
282	Evaluation of 122 advancedâ€stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer, 2016, 122, 249-257.	2.0	67
283	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	1.9	78
284	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology, 2016, 27, 795-800.	0.6	150
285	Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clinical Genitourinary Cancer, 2016, 14, e187-e193.	0.9	1
286	Bone Complications in Patients With Cancer. JAMA Oncology, 2016, 2, 695.	3.4	0
287	Clinical activity of ceritinib in ROS1 -rearranged non-small cell lung cancer: Bench to bedside report. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1419-20.	3.3	29
288	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. Blood, 2016, 128, 480-480.	0.6	5

#	Article	IF	Citations
289	Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients.. Journal of Clinical Oncology, 2016, 34, 10049-10049.	0.8	1
290	Alpha particle radium-223 dichloride (223RaCl2) in high risk osteosarcoma.. Journal of Clinical Oncology, 2016, 34, 11029-11029.	0.8	5
291	Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.. Journal of Clinical Oncology, 2016, 34, 11057-11057.	0.8	1
292	Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.. Journal of Clinical Oncology, 2016, 34, 2517-2517.	0.8	4
293	Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program.. Journal of Clinical Oncology, 2016, 34, 2528-2528.	0.8	5
294	Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates.. Journal of Clinical Oncology, 2016, 34, 3022-3022.	0.8	1
295	Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.. Journal of Clinical Oncology, 2016, 34, 9069-9069.	0.8	10
296	Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 9073-9073.	0.8	5
297	Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies.. Journal of Clinical Oncology, 2016, 34, 9522-9522.	0.8	3
298	ROAR: a phase 2, open-label study in patients (pts) with BRAF V600Eâ€"mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.. Journal of Clinical Oncology, 2016, 34, TPS2604-TPS2604.	0.8	6
299	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget, 2016, 7, 64421-64430.	0.8	17
300	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	0.8	44
301	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget, 2016, 7, 23227-23238.	0.8	23
302	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget, 2016, 7, 35132-35143.	0.8	9
303	Abstract A48: Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR,VEGFR,RET) in children, adolescents, and young adults with advanced solid tumors. , 2016, , .		1
304	Percutaneous transhepatic biliary drainage in hepatopancreaticobiliary cancer: Contemporary efficacy.. Journal of Clinical Oncology, 2016, 34, e21637-e21637.	0.8	0
305	Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.. Journal of Clinical Oncology, 2016, 34, 2546-2546.	0.8	0
306	Symptom clusters in patients with advanced cancer in an early-phase clinical trials clinic.. Journal of Clinical Oncology, 2016, 34, 2540-2540.	0.8	0

#	Article	IF	Citations
307	Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies.. Journal of Clinical Oncology, 2016, 34, 2573-2573.	0.8	0
308	Clinical utilization of precision oncology decision support for genomically-informed cancer therapy.. Journal of Clinical Oncology, 2016, 34, 11605-11605.	0.8	0
309	Clinical next-generation sequencing in sarcomas.. Journal of Clinical Oncology, 2016, 34, 11046-11046.	0.8	0
310	Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response. , 2016, , .		0
311	Abstract 3146: Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers. , 2016, , .		1
312	Abstract CT052: A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a BRAF aberration. , 2016, , .		1
313	Abstract B005: Cytokine production by intratumorally administered activated dendritic cells correlates with survival in a Phase I clinical trial in diverse cancers. , 2016, , .		0
314	STUMP unâ€œstumpedâ€• anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. Journal of Hematology and Oncology, 2015, 8, 66.	6.9	75
315	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer, 2015, 15, 713.	1.1	43
316	Cognitive Changes During Chemotherapy. JAMA Oncology, 2015, 1, 1353.	3.4	3
317	Fast-tracking novel drugs in pediatric oncology. Cell Cycle, 2015, 14, 1127-1128.	1.3	6
318	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of Oncology, 2015, 26, 1012-1018.	0.6	56
319	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	3.2	70
320	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs, 2015, 33, 700-709.	1.2	12
321	Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. BMC Dermatology, 2015, 15, 2.	2.1	15
322	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer, 2015, 89, 76-79.	0.9	58
323	Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncology, 2015, 11, 1-4.	1.1	17
324	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. New England Journal of Medicine, 2015, 373, 726-736.	13.9	1,483

#	Article	IF	Citations
325	Alpha Emitter Radium 223 in High-Risk Osteosarcoma. JAMA Oncology, 2015, 1, 253.	3.4	30
326	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clinical Genitourinary Cancer, 2015, 13, e19-e26.	0.9	18
327	Radium-223 dichloride therapy in breast cancer with osseous metastases. BMJ Case Reports, 2015, 2015, bcr2015211152-bcr2015211152.	0.2	18
328	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. Journal of Clinical Oncology, 2015, 33, 11019-11019.	0.8	8
329	First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2520-2520.	0.8	4
330	Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.. Journal of Clinical Oncology, 2015, 33, 3511-3511.	0.8	10
331	Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.. Journal of Clinical Oncology, 2015, 33, 3520-3520.	0.8	7
332	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. Journal of Clinical Oncology, 2015, 33, 3608-3608.	0.8	2
333	Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or) Tj ETQq1 1 0.784314 rgBT /Over	0.8	5
334	Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience, 2015, 2, 187-192.	0.9	12
335	Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience, 2015, 2, 646-658.	0.9	7
336	Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015, 6, 20099-20110.	0.8	41
337	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget, 2015, 6, 28453-28462.	0.8	9
338	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	0.8	45
339	Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Oncotarget, 2015, 6, 40642-40654.	0.8	45
340	Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies.. Journal of Clinical Oncology, 2015, 33, 605-605.	0.8	0
341	Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.. Journal of Clinical Oncology, 2015, 33, 320-320.	0.8	0
342	A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, TPS2604-TPS2604.	0.8	1

#	Article	IF	Citations
343	Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer.. Journal of Clinical Oncology, 2015, 33, 105-105.	0.8	0
344	Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. Journal of Clinical Oncology, 2015, 33, 2584-2584.	0.8	0
345	Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer.. Journal of Clinical Oncology, 2015, 33, 2597-2597.	0.8	1
346	Comparison of adult oncology phase 1 trials to pediatric oncology phase 1 trials of targeted therapies.. Journal of Clinical Oncology, 2015, 33, 2581-2581.	0.8	0
347	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.. Journal of Clinical Oncology, 2015, 33, 2588-2588.	0.8	1
348	Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers.. Journal of Clinical Oncology, 2015, 33, 11048-11048.	0.8	1
349	Abstract 4263: Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials. , 2015, , .		0
350	Abstract 2499: Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers. , 2015, , .		0
351	Abstract 246: Phase 1 study: Ipilimumab (anti CTLA-4) in combination with Lenalidomide in patients with advanced cancers. , 2015, , .		0
352	Abstract 2413: Rapid, automated BRAF mutation testing of cell-free DNA from plasma of patients with advanced cancers using the novel Idylla platform. , 2015, , .		1
353	Abstract 604: Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary: Implications for personalized medicine. , 2015, , .		0
354	Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discovery Medicine, 2015, 19, 101-8.	0.5	0
355	Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discovery Medicine, 2015, 19, 109-16.	0.5	13
356	Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. PLoS ONE, 2014, 9, e93676.	1.1	32
357	Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring aPIK3CAMutation. Journal of Breast Cancer, 2014, 17, 287.	0.8	7
358	Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223. Advances in Experimental Medicine and Biology, 2014, 804, 291-304.	0.8	44
359	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clinical Cancer Research, 2014, 20, 5956-5963.	3.2	10
360	Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Experimental Hematology and Oncology, 2014, 3, 23.	2.0	27

#	Article	IF	Citations
361	Incidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodes. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, 271-277.	0.2	2
362	Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. Journal of Hematology and Oncology, 2014, 7, 8.	6.9	63
363	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clinical Breast Cancer, 2014, 14, 468-474.	1.1	29
364	Prospects and Pitfalls of Personalizing Therapies for Sarcomas: From Children, Adolescents, and Young Adults to the Elderly. Current Oncology Reports, 2014, 16, 401.	1.8	9
365	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (SutentÂ®) a VEGFR2/PDGFRÎ²/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. Journal of Hematology and Oncology, 2014, 7, 52.	6.9	33
366	Abstract 4700: One size does not fit all: Fingerprinting advanced carcinoma of unknown primary through comprehensive profiling identifies aberrant activation of the PI3K and MAPK signaling cascades in concert with impaired cell cycle arrest. , 2014, , .		1
367	Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine.. Journal of Clinical Oncology, 2014, 32, 10595-10595.	0.8	1
368	A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2524-2524.	0.8	12
369	Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.. Journal of Clinical Oncology, 2014, 32, 8508-8508.	0.8	2
370	Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.. Journal of Clinical Oncology, 2014, 32, e22175-e22175.	0.8	1
371	Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in osteosarcoma.. Journal of Clinical Oncology, 2014, 32, TPS10600-TPS10600.	0.8	4
372	FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors. PLoS ONE, 2014, 9, e89388.	1.1	50
373	Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis. Oncoscience, 2014, 1, 167-179.	0.9	48
374	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. Oncoscience, 2014, 1, 522-530.	0.9	7
375	A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 2014, 1, 614-623.	0.9	26
376	A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget, 2014, 5, 95-102.	0.8	29
377	MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget, 2014, 5, 1837-1845.	0.8	27
378	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354.	0.8	54

#	Article	IF	Citations
379	c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors.. Journal of Clinical Oncology, 2014, 32, 407-407.	0.8	0
380	Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin.. Journal of Clinical Oncology, 2014, 32, 2563-2563.	0.8	0
381	Local and systemic antitumor effects of activated autologous dendritic cells for intratumoral injection: A phase I/II trial.. Journal of Clinical Oncology, 2014, 32, TPS3133-TPS3133.	0.8	0
382	A phase I trial of pazopanib and vorinostat: The role of TP53 mutations.. Journal of Clinical Oncology, 2014, 32, 2576-2576.	0.8	0
383	Rechallenge with anti-EGFRâ€"based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response.. Journal of Clinical Oncology, 2014, 32, 3607-3607.	0.8	4
384	Genomic profiling and precision medicine in 3,745 patients with advanced cancer.. Journal of Clinical Oncology, 2014, 32, e13521-e13521.	0.8	0
385	BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla).. Journal of Clinical Oncology, 2014, 32, e22139-e22139.	0.8	0
386	A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF-mutated advanced malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2628-TPS2628.	0.8	0
387	Clinical next-generation sequencing to identify actionable alterations in a phase I program.. Journal of Clinical Oncology, 2014, 32, 11115-11115.	0.8	0
388	Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience.. Journal of Clinical Oncology, 2014, 32, 10531-10531.	0.8	1
389	A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2639-TPS2639.	0.8	0
390	Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine.. Journal of Clinical Oncology, 2014, 32, e22154-e22154.	0.8	0
391	Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center.. Journal of Clinical Oncology, 2014, 32, e21024-e21024.	0.8	0
392	Abstract LB-170: Droplet digital PCR detection and longitudinal monitoring ofBRAFmutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease. , 2014, , .		0
393	Abstract 5607: BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. , 2014, , .		1
394	Abstract 5080: Clinical next generation sequencing of adolescents and young adult (AYA) patients with cancer reveals aggressive biology: A preliminary report from a major cancer center. , 2014, , .		0
395	The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study. Blood, 2014, 124, 635-635.	0.6	2
396	Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discovery Medicine, 2014, 18, 323-30.	0.5	6

#	Article	IF	Citations
397	Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discovery Medicine, 2014, 18, 331-9.	0.5	8
398	Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. Annals of Hematology, 2013, 92, 1149-1149.	0.8	9
399	Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet Journal of Rare Diseases, 2013, 8, 112.	1.2	41
400	A Tale of Two Histiocytic Disorders. Oncologist, 2013, 18, 2-4.	1.9	11
401	Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewingâ€™s Sarcoma (EWS/FLI1) and Wilmsâ€™ Tumor(WT1). PLoS ONE, 2013, 8, e68985.	1.1	35
402	Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies.. , 2013, , .		1
403	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood, 2013, 122, 3048-3048.	0.6	1
404	Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials.. Journal of Clinical Oncology, 2013, 31, 281-281.	0.8	1
405	Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications. Oncotarget, 2013, 4, 884-889.	0.8	24
406	Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget, 2013, 4, 153-162.	0.8	31
407	Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, 232-232.	0.8	1
408	Abstract 4387: Molecular profiling for actionable aberrations in advanced osteosarcoma.. , 2013, , .		0
409	Abstract A202: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform.. , 2013, , .		0
410	Abstract C198: BRAF mutation testing of archival tumor samples with a novel, rapid, fully-automated molecular diagnostics prototype platform.. , 2013, , .		0
411	Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response.. , 2013, , .		0
412	Abstract C203:BRAFandKRASmutation testing in cell-free DNA and circulating tumor cells from blood of patients with metastatic cancers.. , 2013, , .		0
413	Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist. Molecular Cancer Therapeutics, 2012, 11, 2541-2546.	1.9	53
414	Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside. Journal of Clinical Oncology, 2012, 30, e64-e68.	0.8	42

#	Article	IF	Citations
415	Whole Abdominopelvic Intensity-Modulated Radiation Therapy for Desmoplastic Small Round Cell Tumor After Surgery. International Journal of Radiation Oncology Biology Physics, 2012, 83, 317-326.	0.4	48
416	Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapy. Pediatric Blood and Cancer, 2012, 58, 823-824.	0.8	0
417	How Watching the Movie Zombieland Helps Treatment of Cancer in Teenagers. Journal of Cancer Education, 2012, 27, 188-191.	0.6	1
418	Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers.. Journal of Clinical Oncology, 2012, 30, 10021-10021.	0.8	1
419	Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic.. Journal of Clinical Oncology, 2012, 30, 364-364.	0.8	1
420	Biotargets in Sarcomas: The Past, Present, and a Look into the Future. , 2012, , 419-438.		0
421	Abstract LB-124: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. , 2012, , .		0
422	Abstract 2669: Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience. , 2012, , .		0
423	Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma.. Journal of Clinical Oncology, 2012, 30, e13020-e13020.	0.8	0
424	Ewing's sarcoma: overcoming the therapeutic plateau. Discovery Medicine, 2012, 13, 405-15.	0.5	22
425	Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver â€“ Will it hit the moving target?. Expert Opinion on Investigational Drugs, 2011, 20, 1471-1477.	1.9	4
426	Targeted Therapy of Ewing's Sarcoma. Sarcoma, 2011, 2011, 1-10.	0.7	25
427	Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures. PLoS ONE, 2011, 6, e18424.	1.1	64
428	Phase 1 clinical trials for sarcomas: the cutting edge. Current Opinion in Oncology, 2011, 23, 352-360.	1.1	34
429	There Are Still Some Things Money Canâ€™t Buy. Journal of Cancer Education, 2011, 26, 395-396.	0.6	0
430	Gastric adenocarcinoma in children and adolescents. Pediatric Blood and Cancer, 2011, 57, 524-527.	0.8	36
431	To Ring or Wring the Bell?. Journal of Palliative Medicine, 2011, 14, 968-969.	0.6	0
432	Happy or Unhappy Christmas?. American Journal of Hospice and Palliative Medicine, 2011, 28, 62-62.	0.8	0

#	Article	IF	Citations
433	[90Y]Yttrium Microspheres Radioembolotherapy in Desmoplastic Small Round Cell Tumor Hepatic Metastases. Journal of Clinical Oncology, 2011, 29, e292-e294.	0.8	21
434	99mTc-sestamibi Scan Differentiates Tumor From Other Contrast Enhancing Tissue in Choroid Plexus Tumors. Journal of Pediatric Hematology/Oncology, 2010, 32, 160-162.	0.3	1
435	Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporosis International, 2010, 21, 1041-1045.	1.3	159
436	Adolescent oncology: who cares?â€"the new KID on the block. Supportive Care in Cancer, 2010, 18, 771-773.	1.0	6
437	Neoadjuvant treatment of softâ€tissue sarcoma: A multimodality approach. Journal of Surgical Oncology, 2010, 101, 327-333.	0.8	28
438	Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. Pediatric Blood and Cancer, 2010, 54, 180-181.	0.8	16
439	Resistance to Mammalian Target of Rapamycin Inhibitor Therapy in Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology, 2010, 28, e415-e415.	0.8	50
440	Case 36-2009: A Man with Cough, Hoarseness, and Abnormalities on Chest Imaging. New England Journal of Medicine, 2010, 362, 961-961.	13.9	1
441	A Friend Request: To Accept or Decline?. Journal of Palliative Medicine, 2010, 13, 465-465.	0.6	0
442	Review: Ewing sarcoma treatment: a role for bisphosphonates?. Clinical Advances in Hematology and Oncology, 2010, 8, 503-4.	0.3	3
443	Dose-Modified Oral Chemotherapy in the Treatment of AIDS-Related Non-Hodgkin's Lymphoma in East Africa. Journal of Clinical Oncology, 2009, 27, 3480-3488.	0.8	44
444	Ewingâ€™s Sarcoma: Standard and Experimental Treatment Options. Current Treatment Options in Oncology, 2009, 10, 126-140.	1.3	127
445	Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GTâ€IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome. Pediatric Blood and Cancer, 2009, 53, 1349-1351.	0.8	12
446	Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Experimental Hematology, 2008, 36, 1078-1083.	0.2	47
447	Elevated maternal lipoprotein (a) and neonatal renal vein thrombosis: a case report. Journal of Medical Case Reports, 2008, 2, 106.	0.4	4
448	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New England Journal of Medicine, 2008, 358, 743; author reply 743.	13.9	1
449	Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report. Journal of Medical Case Reports, 2007, 1, 148.	0.4	13
450	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. New England Journal of Medicine, 2007, 357, 1916-1927.	13.9	412

#	Article	IF	Citations
451	Modifiers of risk for infectious complications of cancer therapy in children: The long road ahead. Pediatric Blood and Cancer, 2007, 49, 3-5.	0.8	0
452	Analyses of Prognostic Factors for Survival in East African Patients with AIDS-Related Non-Hodgkinâ€™s Lymphoma (AR-NHL) Treated with Dose Modified Oral Chemotherapy.. Blood, 2006, 108, 3862-3862.	0.6	0
453	Clinical Features of Patients with T Cell Large Granular Lymphocyte Leukemia Distinguish Patients with Splenomegaly and Those Who Benefit from Splenectomy.. Blood, 2006, 108, 4467-4467.	0.6	0